RT Journal Article
SR Electronic
T1 Development of targeted therapies in treatment of glioblastoma
JF Cancer Biology and Medicine
JO Cancer Biol Med
FD China Anti-Cancer Association
SP 223
OP 237
DO 10.7497/j.issn.2095-3941.2015.0020
VO 12
IS 3
A1 Xu, Yuan-Yuan
A1 Gao, Pei
A1 Sun, Ying
A1 Duan, You-Rong
YR 2015
UL http://www.cancerbiomed.org/content/12/3/223.abstract
AB Glioblastoma (GBM) is a type of tumor that is highly lethal despite maximal therapy. Standard therapeutic approaches provide modest improvement in progression-free and overall survival, necessitating the investigation of novel therapies. Oncologic therapy has recently experienced a rapid evolution toward “targeted therapy”, with drugs directed against specific targets which play essential roles in the proliferation, survival, and invasiveness of GBM cells, including numerous molecules involved in signal transduction pathways. Inhibitors of these molecules have already entered or are undergoing clinical trials. However, significant challenges in their development remain because several preclinical and clinical studies present conflicting results. In this article, we will provide an up-to-date review of the current targeted therapies in GBM.